Todays Report: The Alnylam Pharmaceuticals Inc. (ALNY) Lowered to Market Perform at Leerink Swann

The Alnylam Pharmaceuticals Inc. (ALNY) Lowered to Market Perform at Leerink Swann

Leerink Swann lowered shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) from an outperform rating to a market perform rating in a research report report published on Thursday morning. They currently have $40.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $107.00.

A number of other brokerages have also weighed in on ALNY. Credit Suisse Group AG reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Cowen and Company reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Zacks Investment Research lowered Alnylam Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, June 27th. FBR & Co reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a research report on Friday, June 10th. Finally, Chardan Capital reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a research report on Monday, July 11th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $85.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 4.94% during midday trading on Thursday, hitting $34.42. The stock had a trading volume of 2,758,205 shares. The firm’s market cap is $2.95 billion. The firm has a 50 day moving average of $71.80 and a 200 day moving average of $66.24. Alnylam Pharmaceuticals has a 52 week low of $34.18 and a 52 week high of $110.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The firm earned $8.70 million during the quarter, compared to analyst estimates of $8.09 million. During the same period last year, the company earned ($0.85) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up .2% compared to the same quarter last year. Equities research analysts predict that Alnylam Pharmaceuticals will post ($4.68) EPS for the current year.

In related news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the transaction, the chief executive officer now directly owns 148,465 shares in the company, valued at approximately $9,604,200.85. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 4.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in ALNY. Wellington Management Group LLP increased its stake in Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock valued at $749,826,000 after buying an additional 1,288,123 shares during the last quarter. Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 5,385,509 shares of the biopharmaceutical company’s stock valued at $298,843,000 after buying an additional 182,614 shares during the last quarter. Baillie Gifford & Co. increased its stake in Alnylam Pharmaceuticals by 0.3% in the second quarter. Baillie Gifford & Co. now owns 3,390,252 shares of the biopharmaceutical company’s stock valued at $188,125,000 after buying an additional 10,317 shares during the last quarter. Dodge & Cox purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at $139,650,000. Finally, State Street Corp increased its stake in Alnylam Pharmaceuticals by 13.4% in the second quarter. State Street Corp now owns 2,195,504 shares of the biopharmaceutical company’s stock valued at $121,832,000 after buying an additional 258,984 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

About Alnylam Pharmaceuticals

Related posts

Leave a Comment